DJ Abivax Announces Results of its June 6, 2025 Annual General Meeting
ABIVAX
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11-Jun-2025 / 22:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Abivax Announces Results of its June 6, 2025 Annual General Meeting
PARIS, France, June 11, 2025, 10:00 p.m. CEST - Abivax SA (Euronext Paris: FR0012333284 - ABVX / Nasdaq - ABVX)
("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the
body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory
diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by
Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board").
The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for
the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the
directors, as well as delegations granted to the Board related to financial transactions.
The shareholders have also ratified the appointment of Sylvie Grégoire as Chairman and the appointment of Dominik
Höchli, MD as a Board member.
Details of the vote results will be available on the Company's website (www.abivax.com).
*****
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural
regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France
and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the
treatment of moderately to severely active ulcerative colitis. More information on the Company is available at
www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.
Contacts:
Abivax Investor Relations
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878
=----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: 20250611_Abivax_PR_AGM Results 2025
=----------------------------------------------------
Language: English
Company: ABIVAX
5, Rue de La Baume
75008 Paris
France
E-mail: info@abivax.de
Internet: www.abivax.de
ISIN: FR0012333284
Euronext Ticker: ABVX
AMF Category: Inside information / Other releases
EQS News ID: 2153924
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
2153924 11-Jun-2025 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2153924&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
June 11, 2025 16:00 ET (20:00 GMT)
© 2025 Dow Jones News
